Alena Hundertmark

发表

The gatekeeper mutation T315I confers resistance against small molecules by increasing or restoring the ABL-kinase activity accompanied by aberrant transphosphorylation of endogenous BCR, even in loss-of-function mutants of BCR/ABL

O. Ottmann, M. Ruthardt, T. Beissert, 2009, Leukemia.

Targeting of the N‐terminal coiled coil oligomerization interface by a helix‐2 peptide inhibits unmutated and imatinib‐resistant BCR/ABL

C. Nervi, M. Ruthardt, T. Beissert, 2008, International journal of cancer.